Abnormal Glucose tolerance- - Pipeline Insight, 2025
Description
DelveInsight’s, “Abnormal Glucose Tolerance – Pipeline Insight, 2025,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Abnormal Glucose Tolerance pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Abnormal Glucose Tolerance: Overview
Abnormal Glucose tolerance is an umbrella term for a group of metabolic conditions that result in higher than normal blood glucose levels. A condition in which blood sugar is high, but not high enough to be type 2 diabetes. With impaired glucose tolerance one may face a much greater risk of developing diabetes and cardiovascular disease. The WHO (World Health Organisation) indicates that impaired glucose tolerance may be present if people have: Blood glucose of 7.8 mmol/L or more but less than 11.1mmol/L after a 2-hour oral glucose tolerance test OGTT. Various factors increase the risk of developing impaired glucose tolerance including: being overweight or obese, having a family history of diabetes, doing little physical activity, having high blood pressure or high cholesterol and gestational diabetes.
""Abnormal Glucose Tolerance - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Abnormal Glucose Tolerance pipeline landscape is provided which includes the disease overview and Abnormal Glucose Tolerance treatment guidelines. The assessment part of the report embraces, in depth Abnormal Glucose Tolerance commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Abnormal Glucose Tolerance collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Abnormal Glucose Tolerance report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Abnormal Glucose Tolerance Emerging Drugs
Further product details are provided in the report……..
Abnormal Glucose Tolerance: Therapeutic Assessment
This segment of the report provides insights about the different Abnormal Glucose Tolerance drugs segregated based on following parameters that define the scope of the report, such as:
Abnormal Glucose Tolerance: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Abnormal Glucose Tolerance therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Abnormal Glucose Tolerance drugs.
Abnormal Glucose Tolerance Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Abnormal Glucose Tolerance: Overview
Abnormal Glucose tolerance is an umbrella term for a group of metabolic conditions that result in higher than normal blood glucose levels. A condition in which blood sugar is high, but not high enough to be type 2 diabetes. With impaired glucose tolerance one may face a much greater risk of developing diabetes and cardiovascular disease. The WHO (World Health Organisation) indicates that impaired glucose tolerance may be present if people have: Blood glucose of 7.8 mmol/L or more but less than 11.1mmol/L after a 2-hour oral glucose tolerance test OGTT. Various factors increase the risk of developing impaired glucose tolerance including: being overweight or obese, having a family history of diabetes, doing little physical activity, having high blood pressure or high cholesterol and gestational diabetes.
""Abnormal Glucose Tolerance - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Abnormal Glucose Tolerance pipeline landscape is provided which includes the disease overview and Abnormal Glucose Tolerance treatment guidelines. The assessment part of the report embraces, in depth Abnormal Glucose Tolerance commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Abnormal Glucose Tolerance collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Abnormal Glucose Tolerance R&D. The therapies under development are focused on novel approaches to treat/improve Abnormal Glucose Tolerance.
This segment of the Abnormal Glucose Tolerance report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Abnormal Glucose Tolerance Emerging Drugs
- HSK7653: Haisco Pharmaceutical Group Co., Ltd.
- Volagidemab: REMD Biotherapeutics
Further product details are provided in the report……..
Abnormal Glucose Tolerance: Therapeutic Assessment
This segment of the report provides insights about the different Abnormal Glucose Tolerance drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Abnormal Glucose Tolerance
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Abnormal Glucose Tolerance: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Abnormal Glucose Tolerance therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Abnormal Glucose Tolerance drugs.
Abnormal Glucose Tolerance Report Insights
- Abnormal Glucose Tolerance Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Abnormal Glucose Tolerance drugs?
- How many Abnormal Glucose Tolerance drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Abnormal Glucose Tolerance?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Abnormal Glucose Tolerance therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Abnormal Glucose Tolerance and their status?
- What are the key designations that have been granted to the emerging drugs?
- REMD Biotherapeutics
- Haisco Pharmaceutical Group Co., Ltd.
- Novo Nordisk A/S
- Caelus Pharmaceuticals BV
- HSK7653
- Volagidemab
- Liraglutide Pen Injector
- Intestinimonas-capsules
Table of Contents
40 Pages
- Introduction
- Executive Summary
- Abnormal Glucose Tolerance: Overview
- ● Causes
- ● Mechanism of Action
- ● Signs and Symptoms
- ● Diagnosis
- ● Disease Management
- Pipeline Therapeutics
- ● Comparative Analysis
- Therapeutic Assessment
- ● Assessment by Product Type
- ● Assessment by Stage and Product Type
- ● Assessment by Route of Administration
- ● Assessment by Stage and Route of Administration
- ● Assessment by Molecule Type
- ● Assessment by Stage and Molecule Type
- Abnormal Glucose Tolerance – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- ● Abnormal Glucose Tolerance companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Abnormal Glucose Tolerance Collaboration Deals
- ● Company-Company Collaborations (Licensing / Partnering) Analysis
- ● Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
- ● Comparative Analysis
- Drug Name: Company Name
- ● Product Description
- ● Research and Development
- ● Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- ● Comparative Analysis
- HSK7653: Haisco Pharmaceutical Group Co., Ltd.
- ● Product Description
- ● Research and Development
- ● Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- ● Comparative Analysis
- Volagidemab: REMD Biotherapeutics
- ● Product Description
- ● Research and Development
- ● Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- ● Comparative Analysis
- Abnormal Glucose Tolerance Key Companies
- Abnormal Glucose Tolerance Key Products
- Abnormal Glucose Tolerance- Unmet Needs
- Abnormal Glucose Tolerance- Market Drivers and Barriers
- Abnormal Glucose Tolerance- Future Perspectives and Conclusion
- Abnormal Glucose Tolerance Analyst Views
- Abnormal Glucose Tolerance Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
